Research Paper Volume 12, Issue 23 pp 24228—24241
The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction
Figure 5. (A) The ROC curves of the risk scores differentiating pancreatic cancer from normal tissues in the four validation GEO datasets. The clinical and tumor mutation relevance of the three gene signatures. (B–D) The distribution of the risk scores in different AJCC stages in the TCGA cohort. (E–H) The Kaplan-Meier plot (low risk- score vs. high risk- score) of 5-year overall survival in patients in the TCGA cohort. (I–L) The expression level of the risk score in different mutation statuses of KRAS, TP53, CDKN2A, and SMAD4 in the TCGA dataset.